39.96 ± 14.36; 16 female) and 12 antipsychotic-naïve patients with schizophrenia (mean age: 25.75 ± 6.25; 4 female) were analyzed. We observed no differences in [ 11 C]-(+)-PHNO binding in the retina between firstepisode, drug-naïve patients with schizophrenia and healthy controls. Post-mortem retinal tissues from four healthy persons (mean age: 59.75 ± 9.11; 2 female) and four patients with schizophrenia (mean age: 54 ± 17.11; 2 female) were analyzed using a targeted mass spectrometry technique: parallel reaction monitoring (PRM) analysis. Using targeted mass spectrometry, we confirmed that D 3 R are expressed in human retinal tissue ex vivo. 
Introduction
Dopamine (DA) is a major neurotransmitter in the modulation of neural adaptations to light in the retina of mammals (Frederick et al., 1982; Hirasawa et al., 2015; Jackson et al., 2012; Popova, 2014; Tian et al., 2015; Witkovsky, 2004; Zhang et al., 2007) . In this regard, DA D 2 receptors (D 2 R) are thought to mediate several important functional roles. For example, the retinal circadian clock controls the extent and strength of rod-cone coupling (ensuring dim-light signals from rods are received by cones at night, but not in the day) through activation of D 2 R during the daytime (Ribelayga et al., 2008) . Moreover, D 2 R are expressed on Müller glial cells (Biedermann et al., 1995) and may affect photoreceptor survival by regulating the release of neuroprotective factors (De Melo Reis et al., 2008) , especially during stress (Chen et al., 2013) .
It has been established that DA D 2 receptors (D 2 R) are expressed in the retinas of all vertebrate species examined to date (Djamgoz and Wagner, 1992; Nguyen-Legros et al., 1999; Witkovsky and Dearry, 1991) , including humans Stormann et al., 1990) . quantification of D 3 R has been difficult due to a lack of compounds and antibodies selective for D 3 R as opposed to D 2 R (Le Foll et al., 2014) . While evidence of D 3 R mRNA has been observed in the retina of zebrafish (Boehmler et al., 2004) , this has not been observed in the retina of rodents (Cohen et al., 1992; Derouiche and Asan, 1999) ; with several rodent studies employing non-specific antibodies or radioligands for D 2 R and D 3 R (Tran and Dickman, 1992; Veruki, 1997; Zarbin et al., 1986) . Moreover, whether D 3 R are expressed in the retina of humans remains unclear. An un-published abstract suggests that D 3 R mRNA could not be detected in human post-mortem retinal tissue (Prünte et al., 1992) . Moreover, autoradiographic studies have employed nonspecific radioligands for D 2 R and D 3 R (Denis et al., 1990; Zarbin et al., 1986) .
The positron emission tomography (PET) radiotracer [ 11 C]-(+)-PHNO (Wilson et al., 2005) (Doot et al., 2018; Narendran et al., 2006; Searle et al., 2010 Searle et al., , 2013 Tziortzi et al., 2011) . This in vivo preference of [ (Mukherjee et al., 2015) . Using a high-resolution head-dedicated PET camera, we observed what appeared to be significant uptake of [ 11 C]-(+)-PHNO in the retinas of human participants (see Fig. 1 ). Notably, we did not observe similar uptake into the retina with the antagonist radiotracer [
11 C]-raclopride, which does not have significant binding to D 3 R in vivo (Narendran et al., 2006) . In this investigation, we set out to determine whether the [ 11 C]-(+)-PHNO signal in the retina could be meaningfully quantified using typical pharmacokinetic modelling approaches. Given growing evidence of multiple retinal abnormalities in patients with schizophrenia (Adams and Nasrallah, 2017) , we further explored whether [ 11 C]-(+)-PHNO binding in the retina was different between first-episode, drug-naïve patients with schizophrenia, and age-and sex-matched healthy controls. Using targeted mass spectrometry, we then set out to determine whether D 3 R are expressed in post-mortem human retinal tissue. This included retinal samples from healthy persons and age-and sex-matched persons with schizophrenia, to complement our in vivo data with [ 11 C]-(+)-PHNO.
Material and methods

[11C]-(+)-PHNO participants
PET data from healthy persons and drug-naive persons with schizophrenia, previously reported in the literature, were re-analyzed for the current investigation (Graff-Guerrero et al., 2008 Mizrahi et al., 2011) . These studies were approved by the Research Ethics Board of the Centre for Addiction and Mental Health (CAMH), Toronto. Healthy participants were right-handed adults free of any major medical or psychiatric disorders as determined by clinical interview, the (n = 49). These four averaged parametric BP ND maps correspond to contiguous slices.
F. Caravaggio et al. Experimental Eye Research 175 (2018) 32-41 Mini International Neuropsychiatric Interview-Plus (MINI-Plus), basic clinical laboratory tests, and electrocardiography. Participants with schizophrenia were antipsychotic-naïve and met criteria for the diagnosis of schizophrenia or schizoaffective disorder based on the DSM-IV and the MINI-Plus. Participants were excluded if they had a current diagnosis of substance abuse or dependence, a history of clinically significant physical illness, or metal implants precluding the ability to be scanned with MRI. At inclusion and before the PET scan, participants were required to have a negative urine screen for drugs of abuse and/or pregnancy. All participants provided written informed consent. The average age of illness onset for the patient sample was 24. 42 ± 6.75 (range: 17-42) , with an average duration of illness of 16.33 ± 14.74 (range: 2-48) months.
[11C]-(+)-PHNO synthesis & acquisition
A full description of the radiosynthesis of [ 11 C]-(+)-PHNO, as well as how PET images were acquired, can be found in previous publications (Graff-Guerrero et al., 2008; Wilson et al., 2005) . Briefly, [
11 C]-propionyl chloride was reacted with 9-hydroxynaph-thoxazine to generate a [ 11 C]-amide. This was subsequently reduced by lithium aluminium hydride. Purification by HPLC and formulation gave radiochemically pure [ 11 C]-(+)-PHNO as a sterile, pyrogen-free solution.
PET images were acquired using a high-resolution head-dedicated PET camera system (CPS-HRRT; Siemens Molecular Imaging, USA) (GraffGuerrero et al., 2008) . The CPS-HRRT measures radioactivity in 207 brain slices, each with a thickness of 1.2 mm (Graff-Guerrero et al., 2008) . The in-plane resolution was approximately 2.8 mm full-width at half-maximum (FWHM) (Graff-Guerrero et al., 2008 (GraffGuerrero et al., 2008) . The raw data were reconstructed by filteredback projection and the emission data were re-binned into a series of 3D sonograms (Graff-Guerrero et al., 2008) . Scanning time was 90-min in length, wherein 30 frames were defined: 1 to 15 of 1-min duration and 16 to 30 of 5-min duration. A custom-fitted thermoplastic mask (TruScan Imaging, Annapolis) was created for each subject and used with a head fixation system during PET scans to reduce movement during the acquisition (Graff-Guerrero et al., 2008) . [ 11 C]-(+)-PHNO was injected as a bolus followed by a flush of 2 mL saline into an intravenous line placed in an antecubital vein (Graff-Guerrero et al., 2008) . The mean radioactivity dose was 9.38( ± 1.34)mCi, with a specific activity of 1160.82( ± 401.58)mCi/μmol, an injected mass of 2.07( ± 0.46)μg, and an injected mass per kilogram of 0.03( ± 0.008)μg/Kg. None of the participants included in this sample reported nausea associated with [ (Mizrahi et al., , 2010 Rabiner and Laruelle, 2010) .
MRI imaging
Subjects provided a T1-weighted MRI image (TE = 17, TR = 6000, FOV = 22 cm 2D, 256 × 256, slice thickness of 2 mm, NEX = 2) acquired on a 1.5 T Signa scanner (General Electric Medical Systems, Milwaukee, WI). These images were used to enhance the analysis of PET scans, via co-registration (described in detail below, under [ the retina could be observed), employing previous PET guidelines (Bauer et al., 2017 ) (See Fig. 2 ). These manually drawn ROIs were then used to extract time activity curves from each subjects' dynamic PET image in native-space (See Fig. 3 ). This was done with reference to each subjects co-registered T1-weighted MRI image, to confirm the placement of the retina ROIs. The co-registration of each subjects MRI to PET space was done using the normalized mutual information algorithm (Studholme et al., 1997) as implemented in SPM2 (SPM2, Wellcome Department of Cognitive Neurology, London; http://www.fil.ion.ucl.ac. uk/spm). The TACs from the manually drawn retina ROIs were analyzed using both the Simplified Reference Tissue Method (SRTM) (Lammertsma and Hume, 1996 ) and Ichise's Multilinear Reference Tissue Model (MRTM) (Ichise et al., 2003) , both of which have been validated for use with [ 11 C]-(+)-PHNO (Ginovart et al., 2007) . For both models, the cerebellum was used as the reference region to derive a quantitative estimate of binding -binding potential relative to the nondisplaceable compartment (BP ND ) -as defined by the consensus nomenclature for in vivo imaging of reversibly binding radioligands (Innis et al., 2007) . It has been noted for in vivo human studies with [ 11 C]-(+)-PHNO that there is a small displaceable signal in cerebellum (BP ND = ∼0.4) representing binding to D 3 R (Searle et al., 2013) in cerebellar lobes IX and X (Barik and de Beaurepaire, 1996) . Thus, while we have done our best to exclude lobes IX and X in our cerebellar ROI, using the cerebellum as the reference region with [ 11 C]-(+)-PHNO may result in some underestimation of BP ND at D 3 R (Searle et al., 2013) . Moreover, we recognize that use of the SRTM and MRTM is predicated on the assumption that blood flow into and out of the target and reference regions are similar (Salinas et al., 2015) . This assumption may not be true for both the blood-brain barrier (cerebellar reference region) and the retina-brain barrier (retina target region), thus biasing our estimate of BP ND . This poses a limitation in quantification which can only be avoided using arterial sampling of [ 11 C]-(+)-PHNO, which is both invasive and costly. For the second approach (termed "automated"), the basis function implementation of the SRTM (Gunn et al., 1997) was applied to the dynamic PET images to generate parametric voxel-wise BP ND maps using PMOD (v2.7, PMOD Technologies, Zurich, Switzerland). These images were spatially normalized into MNI brain space by Nearest Neighbour Interpolation with a voxel size fixed in 2 × 2 × 2 mm 3 using SPM2. Regional BP ND estimates were then derived from a manually drawn retina ROI defined in MNI space. The drawing of this ROI was aided by superimposing the average of the parametric voxel-wise BP ND maps of all the subjects onto an MNI template.
Post-mortem retinal tissue samples
Post-mortem retinal tissues from four patients with schizophrenia, and four age-and sex-matched healthy controls, were acquired from the St. Michael's Hospital Human Eye Biobank (http://www. stmichaelshospital.com/eye-biobank/; Toronto, Ontario, Canada) (See Table 3 ). Samples were formalin-fixed paraffin-embedded (FFPE).
Sample preparation and high-resolution parallel reaction monitoring (PRM) analyses
Total sample homogenates (approx. 2 μg) were subjected to a modified filter-aided sample preparation (FASP) protocol as previously Caravaggio et al. Experimental Eye Research 175 (2018) 32-41 described (Scifo et al., 2015) , with additional precipitation using an equal volume of 2 M KCL for depletion of residual detergents. Lys-C and tryptic peptides were combined and processed on Pierce C18 Tips reversed phase resin (Thermo Scientific) for desalting and concentration. High-resolution parallel reaction monitoring (HR-PRM) analyses were performed on a Q Exactive HF quadrupole-orbitrap mass spectrometer (Thermo Fisher Scientific) coupled to an EASY nanoflow liquid chromatography (EASY-nLC™) system (Thermo Fisher Scientific). Peptides were separated on a 50 cm column (75 μm inner diameter) packed with PepMap ® RSLC C18 resin at 60°C, using a flow rate of 250 nl/min on a 0%-42% acetonitrile (ACN) in 0.1% formic acid (FA) gradient and Buffer B (80% ACN with 0.1% FA) over 60 min. Column washes were performed on a 30%-90% acetonitrile in 0.1% formic acid gradient for 2 min. The IonMax electrospray ion source settings were: spray voltage, +1900 V and capillary temperature, +250°C. In the PRM method, we only observed charge states as described in the inclusion list and skyline file. The targeted MS/MS was run at an Orbitrap resolution of 30,000 at m/z 200, an AGC target value of 2 × 10 5 , and maximum fill times of 100 ms. The targeted peptide was isolated using a 0.8 m/z unit window. Fragmentation was performed with normalized collision energy (NCE) of 32 eV. In the PRM method, we only observed charge states as described in the inclusion list and skyline file. Seven peptides and their corresponding heavy peptides (Table 4) were comprised in the inclusion list. Target peptides were selected based on in silico cleavage of the proteins using the Peptide Mass feature of ExPASy bioinformatics portal (http://web.expasy.org/peptide_mass/). The following settings were used: enzyme (trypsin); 0 missed cleavage and display the peptides with a mass bigger than 500 Da.
PRM data analysis
Mass spectrometry analysis was performed at the SPARC Biocentre (The Hospital for Sick Children; SickKids, Toronto). We attempted to quantify 4 and 3 unique peptides for D 2 R and D 3 R, respectively (see Table 4 ). However, because of the relatively low protein yield in our FFPE slide samples, only a single unique peptide of either protein was detected and subsequently used for identification. Data analysis and quantification of PRM runs was performed using Skyline software (MacLean et al., 2010) . Relative quantification of D 2 R and D 3 R peptides from schizophrenia patient and control samples was based on the sum of the area under the curves (AUC) of the top three most intense peptide fragments. The use of a subset of three to six fragment ions (with acceptable peak purity) for peptide quantitation has been previously suggested to yield more accurate results than the entire set (Gallien and Domon, 2015; Sundberg et al., 2016) . Endogenous peptides were matched to heavy isotope peptides based on their similar retention times and transition patterns.
Statistical analyses
Statistical analyses were performed using IBM SPSS (v.20) and GraphPad (v.5.0; GraphPad Software, La Jolla California). Normality of variables was determined using the D'Agostino-Pearson test. The significance level for all tests was set at p < .05 (two-tailed). The average measure interclass correlation coefficient (ICC) between manually drawn SRTM and MRTM retina BP ND estimates was 0.91, with a 95% CI from 0.84 to 0.95 (F(48,48) = 11.70, p < .0001). The average measure ICC between the manually and automatically derived SRTM retina BP ND estimates was 0.53, with a 95% CI from 0.19 to 0.73 (F(48,48) = 2.23, p < .003), suggesting that the automatic, parametric SRTM method was less reliable.
Results
The size of the manually drawn retina ROIs (mean ± S.D.) were 4217.22 ( ± 624.97) . We examined whether retina BP ND was correlated with the size of the manually drawn ROIs from which they were derived. Retina SRTM BP ND was not correlated with the total number of voxels (r(47) = 0.18, p = . Fig. 4 ). In the first-episode patients, age of illness onset and illness duration were not correlated with [
11 C]-(+)-PHNO BP ND in the retina (SRTM: age, r (9) = 0.16, p = .63, duration r(9) = -0.27, p = .42; MRTM: age, r (9) = 0.14, p = .68, duration r(9) = -0.22, p = .53).
We employed high-resolution PRM to determine the availability and relative amounts of DA D 2 R and D 3 R receptors in our human retina samples. The choice for PRM analysis was motivated by its sensitivity and selectivity in detecting/quantifying target proteins in complex samples, that are otherwise undetectable by Western blot analysis. Total protein was extracted from the FFPE human retina tissue slides, consisting of 4 biological replicates from schizophrenia patients and control subjects, and subsequently used to generate peptides for PRM analysis. Given the low protein yield of FFPE samples, we did not perform technical replicates for this analysis. Peptide intensities were normalized based on the total ion chromatogram (TIC) intensity of the samples measured in shotgun LC-MS/MS mode, in order to correct for variations in the total peptide amount injected for the different samples. We included 4 and 3 target peptides in our PRM method (Table 4) These unique peptide detections indicated that D 2 R and D 3 R are expressed in the human retina. Notably, D 2 R was significantly decreased in patients with schizophrenia compared to healthy controls (t (6) = 2.57, p = .04). However, there was no statistical difference with regards to levels of D 3 R (t(6) = 1.18, p = .28) (see Fig. 5 ). Fold-change ratios for D 2 R and D 3 R in patients relative to controls are presented in the Supplementary Material.
Discussion
We observed significant uptake of the agonist D 2/3 R radiotracer [ 11 C]-(+)-PHNO into the retina of humans. We examined whether this uptake could be meaningfully quantified using simple pharmacokinetic modelling. We observed that this uptake could be quantified, suggesting that To ascertain whether D 3 R are expressed in the human retina, we employed targeted mass spectrometry in post-mortem retinal tissue. High-resolution PRM analysis revealed that indeed both D 2 R and D 3 R are expressed in the human retina at significant levels. Moreover, D 2 R expression in the retina was reduced in older, chronically treated patients with schizophrenia compared to healthy controls. There was also a non-significant reduction in D 3 R expression observed in patients relative to controls.
Collectively, our post-mortem data demonstrates that both D 2 R and D 3 R are expressed in the human retina and that, on average, the expression of D 3 R is 11-12-times less than that of D 2 R. Given that D 2 R expression in the retina is several orders of magnitude higher than D 3 R expression, it is possible that zero percent of the uptake in the retina is due to [ Collectively, our data also suggests that both D 2 R and D 3 R may be reduced in older, treated patients with schizophrenia. However, this may not be the case in first-episode, drug-naïve patients. This appears prima facie consistent with evidence that DA receptor blockade by antipsychotics may cause degenerative retinopathies in patients with schizophrenia (Fornaro et al., 2002) . Reductions in the retinal nerve fiber layer, macula, ganglion cell layer, and the inner plexiform layer is present in chronically treated patients with schizophrenia (Adams and Nasrallah, 2017; Ascaso et al., 2015; Celik et al., 2016; Lee et al., 2013b; Yilmaz et al., 2016) -although this has not been observed in all studies (Chu et al., 2012; Silverstein et al., 2017) . In this regard, it is worth noting that thinning of the retinal nerve fiber layer and outer retina layers has been associated with neurodegenerative disorders such as Alzheimer's disease (Lu et al., 2010) and frontotemporal degeneration (Kim et al., 2017a) . Thus, it will be important to elucidate the relationship between D 2/3 R expression and structural integrity of the retina across various neuropsychiatric diseases. However, it is currently unclear how chronic antipsychotic exposure affects D 2 R and D 3 R expression in retina, and in turn visual functioning. For example, while several studies have demonstrated contrast sensitivity deficits in patients with schizophrenia (Cadenhead et al., 2013; Cimmer et al., 2006; Skottun and Skoyles, 2007; Slaghuis, 2004) , reports on the effects of antipsychotics on contrast sensitivity have been mixed. Some studies report abnormally low contrast sensitivity in unmedicated patients relative to medicated patients (Chen et al., 2003) , while others report abnormally high baseline sensitivity which is reduced by short-term antipsychotic treatment (Kelemen et al., 2013) . Further in vivo and ex vivo studies are required to examine the relationships between antipsychotic exposure on D 2/3 R expression and contrast sensitivity in patients with schizophrenia. While these aspects could not be examined in our current investigation, we believe this work marks as a first step towards elucidating this kind of information in the future.
Given that dopaminergic functioning in the retina may play diverse roles besides light adaptation (Zhang et al., 2007) , such as contributing to the development of myopia (Nebbioso et al., 2014; Sun et al., 2018) , it will be important to determine whether deficits in visual/retinal functioning in schizophrenia are inherent to the pathophysiology of the disease, or related to chronic D 2/3 R blockade by antipsychotics (Adams and Nasrallah, 2017) . For example, it has been well documented that the adverse ocular effects of chlorpromazine include miosis, blurred vision (caused by paralysis of accommodation), pigmentary changes in the retina, attenuation of retinal vessels, and optic nerve pallor (Oshika, 1995; Siddall, 1965) . Moreover, given that loss of retinal DA has been observed in patients with Parkinson's disease (Harnois and Di Paolo, 1990) , it will be important to determine whether D 3 R expression is altered in vivo and ex vivo, and how this may relate to visual functioning in these patients.
In contrast, evidence suggest that agonism of both DA D 1 receptors (D 1 R) and D 2 R may be neuroprotective (Wakakura, 2001 ) and a potentially effective intervention for ischemic or degenerative disorders in the retina and optic nerve (Li et al., 2012; Yamauchi et al., 2003) . Notably, D 3 R agonism has been suggested to mediate neuroprotective effects on striatal DA neurons (Fiorentini et al., 2015; Kim et al., 2017b) ; although pro-cognitive effects of D 3 R antagonists in general has also been suggested (Nakajima et al., 2013) . Since D 1 R and D 3 R form heterodimers in the striatum (Fiorentini et al., 2015) , it will be important to determine, i) whether D 1 R and D 3 R form heterodimers in the retina, and, ii) whether selective D 3 R agonism can mediate neuroprotective effects against neurodegeneration in the retina. To add to this complexity, it has been well established that D 2 R expression decreases with age in the striatum (Karrer et al., 2017 ) -even in patients with schizophrenia (Graff-Guerrero et al., 2015) -while D 3 R expression may increase with age (Matuskey et al., 2016; Nakajima et al., 2015) . Larger in vivo and ex vivo studies are required to determine whether or not D 3 R increases, while D 2 R decreases, with age in the retina, similar to what has been proposed for the striatum.
There are several limitations with the current investigation. First, our PET analysis was retrospective. Thus, we did not acquire information about visual/retinal functioning in our participants. This important information can be acquired by future prospective [
11 C]-(+)-PHNO studies. Notably, both our first-episode sample and our post-mortem retina samples were relatively small. While both of these samples are difficult to recruit/obtain, it will be important for future studies to employ larger samples in order to be sufficiently powered to detect important associations between retinal D 2/3 R availability and clinical/ cognitive variables. Moreover, future [ 11 C]-(+)-PHNO studies examining the retina should recruit a patient group with an established diagnosis of schizophrenia and/or schizoaffective disorder, to compare with first-episode and healthy controls. Second, in quantifying [
11 C]-(+)-PHNO BP ND in the retina we employed a reference tissue model, which requires several assumptions to be met between the reference and target tissue (i.e., the retina and cerebellum) (Salinas et al., 2015) . Thus, it will be important to further validate our quantification of BP ND in the retina using arterial sampling (Lammertsma, 2017 ). This in turn would help overcome any potential issues regarding underestimation of binding to D 3 R in the retina due to specific binding to D 3 R in the cerebellum. Third, the characterization of our participants in the postmortem retina sample was incomplete. Namely, information about history of psychotic symptoms, history of antipsychotic drug usage, and cause of death was unavailable. Fourth, our retina tissue samples were formalin-fixed paraffin-embedded. It will be important to attempt to replicate our findings using unfixed, fresh tissue. Fifth, it will be important to determine where, and on which cell types, D 3 R are expressed in the human retina. However, this knowledge may be contingent upon future advances in the development of D 3 R selective antibodies and radioligands. Finally, due to limitations in radiosynthesis methods, all [ 11 C]-(+)-PHNO scans are acquired under non-tracer conditions (Gallezot et al., 2012; Searle et al., 2013) . Specifically, tracer conditions (less than 10% D 3 R occupancy by (+)-PHNO) would require an injected mass of 4.5 ng/kg, or 0.3 μg of (+)-PHNO in a 70 kg person Searle et al., 2013) . Thus, given non-tracer conditions, the signal from D 3 R blockade may be underestimated (Girgis et al., 2011) and physiological side-effects from tracer injection may occur (Mizrahi et al., , 2010 Rabiner and Laruelle, 2010) . Notably, it has been reported that a 40 ng/kg mass dose of [ 11 C]-(+)-PHNO is associated with 50% occupancy of D 3 R (Searle et al., 2013 ). In our current investigation, the average injected mass was 30 ng/kg. Thus, our [ 
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